Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 10, 2015 10:52 AM ET


Company Overview of Lupin Pharmaceuticals, Inc.

Company Overview

Lupin Pharmaceuticals, Inc. engages in the development and manufacture of branded and generic pharmaceutical products. It offers generic pharmaceutical products for a range of therapeutic areas; and generic Gatifloxacin Ophthalmic Solution for the treatment of bacterial conjunctivitis. The company also engages in identifying, developing, and marketing prescription drugs for children through distributors in the United States; and manufactures oral and injectable cephalosporin APIs. In addition, it offers oral contraceptives for the prevention of pregnancy in women. Lupin Pharmaceuticals, Inc. was founded in 2003 and is based in Baltimore, Maryland. The company has plants in Mandideep, Auranga...

111 South Calvert Street

Harborplace Tower

21st Floor

Baltimore, MD 21202

United States

Founded in 2003





Key Executives for Lupin Pharmaceuticals, Inc.

Chief Executive Officer and Managing Director
Age: 47
Compensation as of Fiscal Year 2015.

Lupin Pharmaceuticals, Inc. Key Developments

Lupin Pharmaceuticals, Inc. Launches Duloxetine 40mg Delayed-Release Capsules in the US

Lupin Pharmaceuticals, Inc. has launched its Duloxetine 40 mg Delayed-Release (DR) Capsule, which is the first and only generic Duloxetine formulation to become available in 40 mg dosage strength. Lupin is excited to bring this new strength to market, as it adds to the currently-available dosing options for greater flexibility of treatment. Lupin is the only generic manufacturer to offer all Duloxetine dosage strengths ­ the 20 mg, 30 mg, 60 mg, and now the newest 40 mg. Lupin's generic Duloxetine 40 mg DR capsules are therefore the first and only capsule available for patients in this dosage strength.

Horizon Pharma plc Files Patent Infringement Lawsuits Against Actavis Laboratories UT, Inc., Actavis, Inc., Allergan plc, Amneal Pharmaceuticals, LLC, IGI Laboratories, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd

Horizon Pharma plc announced it has filed patent infringement lawsuits in the United States District Court for the District of New Jersey against Actavis Laboratories UT, Inc., Actavis, Inc., and Allergan plc (collectively Actavis), Amneal Pharmaceuticals, LLC (Amneal), IGI Laboratories, Inc. (IGI), Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin), and Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries Ltd. (collectively Taro) related to Abbreviated New Drug Applications filed with the U.S. Food and Drug Administration to market a generic version of PENNSAID(r) (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). The lawsuits claim infringement of Horizon's newly issued U.S. Patent No. 9,066,913 titled 'Diclofenac Topical Formulation', which covers PENNSAID 2%.

Lilly and Acrux File Patent Infringement Lawsuit Against Lupin Pharma

Acrux announced that Eli Lilly and Co., Eli Lilly Export S.A., and Acrux DDS Pty Ltd. have filed a lawsuit against Lupin Pharmaceuticals Inc. for infringement of issued US patents that cover Axiron. The patents are owned by Acrux DDS Pty Ltd, a wholly-owned subsidiary of Acrux Limited, and are exclusively licensed to Lilly. The lawsuit was filed in the United States District Court for the Southern District of Indiana in response to a notice letter sent by Lupin regarding its filing with the FDA of an Abbreviated New Drug Application (ANDA) for a Testosterone Metered Dose Transdermal Solution. The letter stated that the ANDA contains Paragraph IV certifications with respect to US Patents 8,419,307, 8,435,944, 8,784,878, 8,807,861 and 8,993,520, which are expected to expire between 2026 and 2030. These patents include claims relating to the application of testosterone formulations to the underarm and to the applicator used to apply Axiron.

Similar Private Companies By Industry

Company Name Region
Suneva Medical, Inc. United States
Sova Pharmaceuticals, Inc. United States
Particle Sciences, Inc. United States
MediNiche, Inc. United States
OmniActive Health Technologies, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Lupin Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at